ATHE

Alterity Therapeutics Ltd

Alterity Therapeutics Ltd (ATHE) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
B+
Factor Score 3.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.8
Rev Growth YoY 74.6%
Gross Margin 97.5%
Price Return 3M -2.8%
Price Return 12M -12.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 12.0
ROE -47.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) B (3.3) B+ (3.7) C (2.4) C- (1.9) C+ (2.8)
2026-08-04 C+ (2.7) B (3.3) B+ (3.7) C (2.4) C- (1.9) C+ (2.8)
2026-08-03 C+ (2.7) C+ (2.7) B (3.4) C (2.4) C- (2.0) C+ (2.6)
2026-08-02 C+ (2.7) C+ (2.7) B (3.4) C (2.4) C- (1.9) C+ (2.6)